VectorialDATA
Stocks/EIS

EIS — iShares MSCI Israel ETF

ETFMiddle EastIsraelBlockchain certified

Price when we picked it (Jun 16, 2026)

$125.61

P/E Ratio

—

P/E Forward

—

Dividend

1.14%

Market Cap

$1.03B

EPS

—

Consensus

ETF — index basket (no individual rating)

What they do

iShares MSCI Israel ETF (NYSE Arca: EIS) is an exchange-traded fund (ETF), not an individual company. An ETF is a basket of many stocks packaged into a single instrument you buy and sell like a stock. It's issued by iShares (BlackRock).

What it holds: it tracks the MSCI Israel index, which groups the large- and mid-cap companies of Israel (~129 companies, ~85% of the country's investable market).

Its biggest positions (top 10, ~Jun 2026):

  • Teva Pharmaceutical (pharma) ~8.8%
  • Bank Leumi (bank) ~8.0%
  • Bank Hapoalim (bank) ~7.0%
  • Tower Semiconductor (chips) ~6.9%
  • Elbit Systems (defense) ~5.4%
  • Nova (chip equipment) ~3.4%, Phoenix Financial (insurance) ~3.3%, Enlight Renewable Energy ~3.2%, Israel Discount Bank ~3.0%, Mizrahi Tefahot Bank ~2.6%

The dominant themes: banking (Leumi, Hapoalim, Discount, Mizrahi add up to ~20% of the fund), health (Teva), semiconductors (Tower, Nova) and defense (Elbit) — the heart of the 'startup nation'.

Costs and income: it charges an expense ratio of 0.59% a year and pays a modest dividend of ~1.1% a year (semi-annual distribution), which comes from the dividends of the Israeli companies it holds. Assets (AUM): ~$1.0 billion.

Why it enters the portfolio: even though it's a basket and not a single company, it also pays dividends — it fits the 'own things that pay you' thesis — and gives diversified exposure to a developed, resilient and very tech-heavy economy for a reasonable fee. It also reinforces today's pick: Bank Hapoalim lives inside this fund.

Why we like it

EIS at $125.61 is the simplest, most diversified way to get exposure to Israel — the 'startup nation' — in a single buy, without depending on one company. Specific reasons:

  • Exposure to the whole Israeli economy at once: solid, cheap banks (Leumi, Hapoalim, Discount, Mizrahi ~20% of the fund), the world's largest generics pharma (Teva), chipmakers (Tower, Nova) and defense champion Elbit — one buy gives you finance, health, semiconductors and defense.
  • Proven resilience: despite years of geopolitical tension and war in the region, the Israeli market has been surprisingly resilient — it's a developed economy, not a fragile emerging market.
  • Defense theme with a tailwind: Elbit Systems and the Israeli defense ecosystem benefit from rising global military spending.
  • Reasonable fee (0.59%) and it pays you dividends (~1.1%): unlike betting on a single company, this basket distributes the dividend from its ~129 companies, twice a year.
  • Real diversification: instead of picking one bank or one Israeli tech name, you hold the biggest ones in a single instrument.
  • Synergy with the portfolio: today we also bought Bank Hapoalim separately — EIS gives you that bank PLUS the rest of Israel. It's country exposure, diversified and with some income.

Key Risk

Risks:

  • Geopolitical risk — #1: Israel sits in one of the world's most conflict-prone regions; a war or escalation (with Iran, Gaza, Lebanon) can hit the whole market at once and without warning. It's the risk that defines this ETF.
  • Currency risk (the shekel): the ETF trades in dollars but its stocks are in Israeli shekels; if the shekel weakens against the dollar, your return drops even if the stocks rise locally.
  • Concentration: the 10 largest names are more than half the fund, and a single sector (banking) weighs ~20% — it's not 'infinitely diversified Israel'.
  • Dependence on Teva: the biggest position is Teva (~8.8%), a pharma with a lot of historical debt and exposed to the generics price war; if it stumbles, the fund feels it.
  • Modest dividend (~1.1%): it pays less than our other ETFs (FLKR ~2%, EZA ~6%) — the thesis here is exposure + resilience, not high income.
  • No 'active management': an ETF tracks the index blindly — if the index is heavy in banking or in Teva, you carry that imbalance.

This is educational and informational content, not financial advice. Always consult a qualified financial advisor before making investment decisions.

Vectorial Data picked EIS on Jun 16, 2026 at $125.61.

Full Research

iShares MSCI Israel ETF (EIS) — Full Research

Price: $125.61 | Type: ETF | Expense ratio: 0.59% | Div Yield: ~1.1% | AUM: ~$1.0B USD


⚠️ This is an ETF, not a company

EIS is a basket of ~129 large- and mid-cap Israeli companies packaged into a single instrument. It has no CEO and no single business: it's diversified exposure to a country. Issuer: iShares (BlackRock). Index: MSCI Israel.

What it holds (top 10, ~Jun 2026)

#CompanySectorWeight
1Teva PharmaceuticalHealth (generics)8.8%
2Bank LeumiBank8.0%
3Bank HapoalimBank7.0%
4Tower SemiconductorChips6.9%
5Elbit SystemsDefense5.4%
6NovaChip equipment3.4%
7Phoenix FinancialInsurance3.3%
8Enlight Renewable EnergyRenewables3.2%
9Israel Discount BankBank3.0%
10Mizrahi Tefahot BankBank2.6%

Top 10 ≈ 51% of the fund. Banking alone (Leumi + Hapoalim + Discount + Mizrahi) ≈ 20%.

Dominant themes

ThemeNames
Banking (~20%)Leumi, Hapoalim, Discount, Mizrahi
HealthTeva (the world's largest generics maker)
SemiconductorsTower, Nova
DefenseElbit Systems

Key data

MetricValue
Expense ratio0.59% /year
Dividend yield (TTM)~1.1% (semi-annual distribution)
AUM~$1.0 billion
No. of holdings~129

Anchor Fact

Buying EIS is buying the heart of the 'startup nation' in a single trade: its four big banks, its pharma giant Teva, its chipmakers (Tower, Nova) and its defense champion Elbit. And despite living in one of the planet's most conflict-prone regions, the Israeli market has historically been resilient — it's a developed economy, not a fragile emerging one. Fun fact: Bank Hapoalim, our other pick today, is the fund's third-largest position.

Top Risks

  • Geopolitical — a regional war/escalation can hit everything at once
  • Currency (shekel) — trades in USD, holdings in shekels
  • Concentration — top 10 ≈ 51%, banking ≈ 20%
  • Dependence on Teva — biggest position, historical debt + generics
  • Modest dividend (~1.1%) — less than FLKR/EZA

Why does it enter the portfolio?

Even though it's a basket and not a single company, it also pays dividends (~1.1%), fits the 'own things that pay you' thesis, and gives cheap (0.59%) diversified exposure to a developed, tech-heavy and resilient economy. It also reinforces today's pick: Bank Hapoalim lives inside the fund.

Thesis in one line

The simplest way to get exposure to Israel — its banking, Teva, its chips and its defense — in a single buy, for a 0.59% fee and with some dividend, betting on the resilience of a developed economy in a tough region.

Research date: 16 Jun 2026 | Next review: Dec 2026

This is not financial advice.

More picks in ETF

See all ETF picks →

More picks from Israel

See all picks from Israel →
Researched: Jun 16, 2026Updated: Jun 16, 2026Next review: Dec 16, 2026

This is not financial advice. Consult a certified financial advisor.

The author may hold positions in the securities discussed.

Past performance does not guarantee future results.